Literature DB >> 7840563

Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods.

G A Pankuch1, M R Jacobs, S F Rittenhouse, P C Appelbaum.   

Abstract

This study evaluated the susceptibility of 123 Xanthomonas maltophilia strains to ticarcillin, ticarcillin-clavulanate, ampicillin, amoxicillin-clavulanate, ampicillin-sulbactam, piperacillin, piperacillin-tazobactam, imipenem, and ciprofloxacin by Kirby-Bauer disk, E test, and Sensititre dehydrated microdilution MIC and conventional agar dilution MIC methodology. Intermediate susceptibility breakpoints for members of the family Enterobacteriaceae were used. When results were analyzed as MICs for 50 and 90% of the strains tested and percentages of strains susceptible at the breakpoint, good correlation between the methods was observed, with ticarcillin-clavulanate clearly the most active beta-lactam by all four methods. However, when the various methods were compared with the agar dilution methodology by regression analysis, poor r2 values (0.3 to 0.7) were obtained for compounds with sufficient on-scale values to permit analysis. When the number of strains with log2 ratios of reference agar dilution MICs to test MICs of +3 to -3 were analyzed, correlation was also poor, with many major and very major discrepancies for all methods tested. Results obtained with time-kill studies of nine strains with discrepant ticarcillin-clavulanate MICs appeared to correlate best when compared at 24 h with agar dilution MICs. The concentration of ticarcillin-clavulanate required to reduce the colony count by > or = 2 log10 reduction values for eight of nine strains compared with that for growth controls was < or = 16.0/2.0 micrograms/ml at 6 h and ranged from 16.0/2.0 micrograms/ml to 128.0/2.0 micrograms/ml at 24 h. The susceptibility method of choice for X. maltophilia has not yet been standardized, but time-kill studies correlated best with agar dilution MICs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7840563      PMCID: PMC284737          DOI: 10.1128/AAC.38.10.2317

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Classification of beta-lactamases: groups 2c, 2d, 2e, 3, and 4.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

2.  In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents.

Authors:  N Khardori; A Reuben; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

3.  Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873.

Authors:  Y Saino; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

4.  Purification and properties of inducible penicillin beta-lactamase isolated from Pseudomonas maltophilia.

Authors:  Y Saino; F Kobayashi; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

5.  Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro.

Authors:  M Lecso-Bornet; J Pierre; D Sarkis-Karam; S Lubera; E Bergogne-Berezin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

6.  Antibiotic susceptibility and outer membrane proteins of clinical Xanthomonas maltophilia isolates.

Authors:  W Cullmann
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

7.  In vitro susceptibility of 33 clinical case isolates of Xanthomonas maltophilia. Inconsistent correlation of agar dilution and of disk diffusion test results.

Authors:  P Hohl; R Frei; P Aubry
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Sep-Oct       Impact factor: 2.803

8.  Infections caused by Pseudomonas maltophilia with emphasis on bacteremia: case reports and a review of the literature.

Authors:  J J Zuravleff; V L Yu
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec

9.  Effect of divalent cations in bacteriological media on the susceptibility of Xanthomonas maltophilia to imipenem, with special reference to zinc ions.

Authors:  P M Hawkey; D Birkenhead; K G Kerr; K E Newton; W A Hyde
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

10.  Effect of media composition on the susceptibility of Xanthomonas maltophilia to beta-lactam antibiotics.

Authors:  G Bonfiglio; D M Livermore
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

View more
  19 in total

1.  Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies.

Authors:  M L Cohn; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Pseudo-, Xantho-, and now Stenotrophomonas maltophilia: New kid on the block.

Authors:  J Conly; S Shafran
Journal:  Can J Infect Dis       Date:  1996-03

3.  Antibiotic resistance of Stenotrophomonas maltophilia strains isolated from captive snakes.

Authors:  P Hejnar; M Kolár; P Sauer
Journal:  Folia Microbiol (Praha)       Date:  2010-03-25       Impact factor: 2.099

Review 4.  Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

5.  Occurrence of variants with temperature-dependent susceptibility (TDS) to antibiotics among Stenotrophomonas maltophilia clinical strains.

Authors:  P Hejnar; M Kolár; V Hájek; D Koukalová; P Hamal
Journal:  Folia Microbiol (Praha)       Date:  2001       Impact factor: 2.099

Review 6.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

7.  Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia.

Authors:  J L Muñoz; M I García; S Muñoz; S Leal; M Fajardo; J A Garćia-Rodríguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-11       Impact factor: 3.267

8.  Comparison of E test and agar dilution for antimicrobial susceptibility testing of Stenotrophomonas (Xanthomonas) maltophilia.

Authors:  J D Yao; M Louie; L Louie; J Goodfellow; A E Simor
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

9.  Double-disk synergy test positivity in Stenotrophomonas maltophilia clinical strains.

Authors:  P Hejnar; M Kolár; Z Chmela
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

10.  Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.